The effect of T-MSCs was evaluated in BALB/c mice that were divided into 4 groups (negative control group nasal polyp group T-MSC group and T-MSC(AD) group (T-MSC incubated with adipogenic differentiated medium)). After induction of OVA- induced ERSwNP model, T-MSCs were administered intravenously (T-MSC and T-MSC(AD) groups) on weeks 5 to 12 (once per week) and subsequent OVA+SEB challenge was conducted until 12 weeks. Several parameters of inflammation including polyp formation were evaluated including cytokine, chemokine and adhesion molecules in nasal mucosa, spleen and lymph node.
Intravenous injection of T-MSCs significantly reduced allergic symptoms, eosinophil, neutrophil, nasal polyp count and serum OVA specific-IgG1 levels. Moreover, the nasal, lymph node and systemic Th2 cytokine profile and innate cytokines such as IL-25 and IL-33, and chemokines (CCL11, CCL24, Cxcl1, CxCl2, ICAM1 and VCAM1) expression were reduced in T-MSCs injected groups, as compared to the nasal polyp group. Usually T-MSC(AD) group showed better inhibitory effects of inflammation than T- MSC group. T-MSCs injected groups have significantly increased Treg cells in cervical lymph node, as compared to the nasal polyp group.
Administration of T-MSCs effectively reduced polyp formation, inflammatory cell influx, cytokine profile, chemokine molecule expression, and T-cell subset distribution, suggestive of the mechanism of reduced CRS inflammation and less polyp formation in mouse model of ERSwNP. Therefore, T-MSC treatment is potentially an alternative therapeutic modality in CRSwNPs